Aklief (Trifarotene 0.005% Cream) for Acne Vulgaris
Apply Aklief (trifarotene 0.005% cream) once daily in the evening as a thin layer to affected areas of the face and/or trunk on clean, dry skin, starting with one pump actuation for the face and adjusting coverage as needed for truncal acne. 1
Dosing Algorithm
Facial acne:
- Use one pump actuation to cover the entire face (forehead, cheeks, nose, and chin) 1
Truncal acne:
- Two pump actuations for upper trunk (reachable upper back, shoulders, chest)
- One additional pump actuation for middle and lower back if acne is present 1
Application technique:
- Apply in the evening only
- Skin must be clean and dry
- Use a thin layer only
- Avoid eyes, lips, paranasal creases, and mucous membranes 1
Patient Age Requirements
Approved for patients ≥9 years of age 1
This is notably younger than traditional tazarotene formulations (0.05% and 0.1%), which have not established safety and efficacy in patients with acne <12 years of age 2. Aklief represents a newer-generation retinoid (trifarotene) with a different safety profile than older tazarotene formulations.
Essential Supportive Care
Start moisturizer immediately from day one of treatment 1
This is critical—do not wait for irritation to develop. The FDA label explicitly recommends moisturizer use "as frequently as needed from the initiation of treatment" 1. Maximum severity of irritation typically occurs within the first 4 weeks 1.
Managing Irritation
If patients develop erythema, scaling, dryness, or stinging/burning:
- Continue moisturizer (increase frequency)
- Reduce application frequency (alternate days)
- Temporarily suspend if reactions are severe
- Discontinue only if severe reactions persist despite modifications 1
Most adverse events (83-98%) are mild to moderate 3, and severity typically decreases with continued use 1.
Critical Safety Precautions
Pregnancy status: Category X contraindication 2
Unlike Aklief's specific FDA label which lists "None" for contraindications 1, traditional tazarotene formulations are absolutely contraindicated in pregnancy 2. While the Aklief label doesn't explicitly state pregnancy category, all retinoids carry teratogenic risk and pregnancy should be ruled out before initiating treatment.
Sun protection is mandatory:
- Minimize exposure to sunlight and sunlamps
- Use sunscreen products over treated areas
- Wear protective clothing when exposure cannot be avoided
- Weather extremes (wind, cold) may increase irritation 1
Avoid on compromised skin:
- Do not apply to cuts, abrasions, eczematous skin, or sunburned skin
- Avoid "waxing" as a depilatory method on treated skin 1
Clinical Context and Positioning
Topical retinoids are the core of topical acne therapy because they are comedolytic, resolve microcomedone precursor lesions, and are anti-inflammatory 2. They enhance any topical acne regimen and allow maintenance of clearance after discontinuing oral therapy 2.
Aklief (trifarotene) is a fourth-generation retinoid that selectively targets retinoic acid receptor-gamma (RAR-γ), which is the predominant RAR in the skin 4. This selective binding may contribute to its efficacy profile.
The 2024 AAD guidelines make a strong recommendation for topical retinoids in acne management 4, and combining topical therapies with multiple mechanisms of action is recommended as good practice 4.
Combination Therapy Considerations
Compatible combinations:
- Benzoyl peroxide (use at different times of day to avoid potential oxidation)
- Topical antibiotics (clindamycin)
- Oral antibiotics when indicated 4
Avoid concurrent use with:
- Other potentially irritating topical products (use with caution)
- Keratolytic agents
- Photosensitizing agents 2
Expected Timeline
Efficacy typically becomes apparent within 4-12 weeks of consistent use 1, 3. In clinical trials with traditional tazarotene formulations, median percentage changes in lesion counts showed significant improvement by week 12 3.
Common Pitfall to Avoid
Do not discontinue prematurely due to initial irritation. The first 4 weeks typically show maximum irritation severity, which then decreases with continued use 1. Proper moisturizer use from day one and patient education about this expected timeline prevents unnecessary discontinuation.